MedTrace Logo

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

NCT02742727 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-12-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

Conditions

  • Acute Myeloid Leukemia
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • T-cell Prolymphocytic Leukemia
  • T-cell Large Granular Lymphocytic Leukemia
  • Peripheral T-cell Lymphoma, NOS
  • Angioimmunoblastic T-cell Lymphoma
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Enteropathy-type Intestinal T-cell Lymphoma
  • Hepatosplenic T-cell Lymphoma

Interventions

BIOLOGICAL

anti-CD7 CAR-pNK cells

The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.

Sponsors & Collaborators

  • The First People's Hospital of Hefei

    collaborator OTHER

  • Hefei Binhu Hospital

    collaborator OTHER

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lin Yang, Ph.D. · PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-03-31
Completion
2018-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742727 on ClinicalTrials.gov